Susceptibility of HIV-2, Siv and Shiv to Various Anti-HIV-1 Compounds: Implications for Treatment and Postexposure Prophylaxis
- M. Witvrouw, C. Pannecouque, W. Switzer, T. Folks, E. Clercq, W. Heneine
- Biology, MedicineAntiviral Therapy
- 1 January 2004
Findings support the use of NRTIs, tenofovir, but not NN RTIs, for treating HIV-2-infected persons or for prophylaxis against HIV- 2 and SIV, and show co-receptor antagonists such as AMD3100 show promising anti-HIV-2 therapeutic modalities.
Sulfated polysaccharides extracted from sea algae as potential antiviral drugs.
Integrase Mutants Defective for Interaction with LEDGF/p75 Are Impaired in Chromosome Tethering and HIV-1 Replication*
HIV-1 virus harboring a single mutation that disrupts integrase-LEDGF/p75 interaction, resulted in defective HIV-1 replication and it is found that LEDGF/ p75 tethers HIV- 1 integrase to chromosomes and that this interaction may be important for the integration process and the replication of HIV-2.
Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100
The bicyclam JM3100, in which the cyclam moieties are tethered by an aromatic bridge, inhibits the replication of various HIV-1 and HIV-2 strains in various cell lines at a 50% effective concentration (EC50) of 1 to 10 ng/ml, which is about 100-fold lower than the concentration required for JM2763 to inhibit HIV replication and at least 100,000-fold higher than the cytotoxic concentration (> 500 micrograms/ml).
Preclinical Profile of BI 224436, a Novel HIV-1 Non-Catalytic-Site Integrase Inhibitor
BI 224436 has drug-like in vitro absorption, distribution, metabolism, and excretion properties, including Caco-2 cell permeability, solubility, and low cytochrome P450 inhibition, and has an additive effect in combination with most approved antiretrovirals, including INSTIs.
Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV.
- M. Witvrouw, C. Pannecouque, K. Van Laethem, J. Desmyter, E. De Clercq, A. Vandamme
- Biology, ChemistryAIDS (London)
- 20 August 1999
The data demonstrate that NNRTI are not exclusively specific for HIV-1 but are also inhibitory to different HIV-2 and SIV strains.
Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360
Integrase-chimeric virus technology confirmed that the integrase mutations are indeed fully responsible for the resistance phenotype of IIIB/S-1360res, the first HIV-1 integrase strand transfer inhibitor that has entered clinical development.
Antiviral activity against human immunodeficiency virus type 1 (HIV‐1) and type 2 (HIV‐2) of ethnobotanically selected Ethiopian medicinal plants
- K. Asres, F. Bucar, T. Kartnig, M. Witvrouw, C. Pannecouque, E. De Clercq
- ChemistryPhytotherapy Research
- 1 February 2001
Ethiopian medicinal plants used for the treatment of a variety of ailments including infectious diseases were screened for activity against human immunodeficiency virus type 1 and type 2 and polar extracts derived from 21 plants belonging to 14 families exhibited inhibition of viral growth at subtoxic concentrations.
Resistance of Human Immunodeficiency Virus Type 1 to the High-Mannose Binding Agents Cyanovirin N and Concanavalin A
Recombination of the mutated gp160 genes of the strains resistant to CV-N or ConA into a wild-type background fully reproduced the (cross-)resistance profiles of the originally selected strains, pointing to the impact of the N-glycan mutations on the phenotypic resistance profiles of both selected strains.
Activity of a Sulfated Polysaccharide Extracted from the Red Seaweed Aghardhiella Tenera against Human Immunodeficiency Virus and Other Enveloped Viruses
GS represents a natural polysaccharide with broad-spectrum activity against a number of important viral pathogens and proved active not only against HIV-1 and HIV-2 but also against other enveloped viruses, i.e. herpes-, toga-, arena-, myxo- and rhabdoviruses.